BiO2 Medical, a San Antonio, Texas-based medical device manufacturer, has completed a $13.7M Series B round of funding.
The round, which was led by Targeted Technology Fund and Pasadera Capital, also included the conversion of a $1m State of Texas Emerging Technology Fund (ETF) award.
Led by Christopher E. Banas, Chairman and Chief Executive Officer, and Dr. Luis F. Angel, Chief Medical Officer, BiO2 Medical is developing the AngelTM Catheter, a central venous catheter and Inferior Vena Cava (IVC) filter combination device, intended to protect against potentially fatal Pulmonary Embolism (PE) in critically ill patients. The funding has allowed the company, which has with corporate offices in and R&D and manufacturing operations in Golden, Colorado, to complete Design Verification Testing in support of CE Mark submission, initiate a first in human clinical study in Medellin, Colombia, and conduct a Pre-IDE Meeting with FDA.
FinSMEs
27/03/2012